Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The momentum is there! Just wait patiently.
Did I miss something, are we sitting at 0 volume for the day? No we aren't we have over 600K shares. Close to $100K changed hands.
BREAKING NEWS: UPLIST TO NATIONAL EXCHANGE IN 2021
Management has the following 2021 Strategic Goals:
- Strive to achieve over $50 million in sales.
- Expansion of COVID-19 testing and vaccination programs.
- Completion of telehealth integration with the roll out of the Eagle Force Digital Passport program.
- Nationwide launch of ClearMetrX 340B TPA services.
- Secure additional not-for-profit healthcare contracts and long-term care facility relationships.
- Achieve full enterprise profitability and earnings growth.
- Become SEC-registered and fully reporting.
- Complete an uplist to a national exchange.
$40 Million NET REVENUES in 2020, does you current penny investment company have that?
Hit $.27 in 2018 with just 20 million net revenues.
Comparison list of 2021 vs 2018:
1. $40 million NET revenues instead of $20 million
2. SEC Registration nearing completion (filed November 9, 2020)
3. Potential Merger to make us a $100 million NET revenue company.
4. Uplist to higher exchange soon after.
5. New telehealth partnership.
6. New huge square footage facilities in both Miami (11,000 sq ft) and Orlando (3,700 sq ft).
7. Covid Revenue streams, testing and vaccinations.
8. 323% Exponential Growth in 340B Dispensing and Fees.
BREAKING NEWS: $RXMD $.153 Up 395% since January. OTCQB Stock.
UPLIST TO NATIONAL EXCHANGE IN 2021
Management has the following 2021 Strategic Goals:
- Strive to achieve over $50 million in sales.
- Expansion of COVID-19 testing and vaccination programs.
- Completion of telehealth integration with the roll out of the Eagle Force Digital Passport program.
- Nationwide launch of ClearMetrX 340B TPA services.
- Secure additional not-for-profit healthcare contracts and long-term care facility relationships.
- Achieve full enterprise profitability and earnings growth.
- Become SEC-registered and fully reporting.
- Complete an uplist to a national exchange.
$40 Million NET REVENUES in 2020, does you current penny investment company have that?
Hit $.27 in 2018 with just 20 million net revenues.
Comparison list of 2021 vs 2018:
1. $40 million NET revenues instead of $20 million
2. SEC Registration nearing completion (filed November 9, 2020)
3. Potential Merger to make us a $100 million NET revenue company.
4. Uplist to higher exchange soon after.
5. New telehealth partnership.
6. New huge square footage facilities in both Miami (11,000 sq ft) and Orlando (3,700 sq ft).
7. Covid Revenue streams, testing and vaccinations.
8. 300% Exponential Growth in 340B Dispensing and Fees.
BREAKING NEWS: $RXMD $.153 Up 395% since January. OTCQB Stock.
UPLIST TO NATIONAL EXCHANGE IN 2021
Management has the following 2021 Strategic Goals:
- Strive to achieve over $50 million in sales.
- Expansion of COVID-19 testing and vaccination programs.
- Completion of telehealth integration with the roll out of the Eagle Force Digital Passport program.
- Nationwide launch of ClearMetrX 340B TPA services.
- Secure additional not-for-profit healthcare contracts and long-term care facility relationships.
- Achieve full enterprise profitability and earnings growth.
- Become SEC-registered and fully reporting.
- Complete an uplist to a national exchange.
$40 Million NET REVENUES in 2020, does you current penny investment company have that?
Hit $.27 in 2018 with just 20 million net revenues.
Comparison list of 2021 vs 2018:
1. $40 million NET revenues instead of $20 million
2. SEC Registration nearing completion (filed November 9, 2020)
3. Potential Merger to make us a $100 million NET revenue company.
4. Uplist to higher exchange soon after.
5. New telehealth partnership.
6. New huge square footage facilities in both Miami (11,000 sq ft) and Orlando (3,700 sq ft).
7. Covid Revenue streams, testing and vaccinations.
8. 300% Exponential Growth in 340B Dispensing and Fees.
BREAKING NEWS: $RXMD $.153 Up 395% since January. OTCQB Stock.
UPLIST TO NATIONAL EXCHANGE IN 2021
Management has the following 2021 Strategic Goals:
- Strive to achieve over $50 million in sales.
- Expansion of COVID-19 testing and vaccination programs.
- Completion of telehealth integration with the roll out of the Eagle Force Digital Passport program.
- Nationwide launch of ClearMetrX 340B TPA services.
- Secure additional not-for-profit healthcare contracts and long-term care facility relationships.
- Achieve full enterprise profitability and earnings growth.
- Become SEC-registered and fully reporting.
- Complete an uplist to a national exchange.
$40 Million NET REVENUES in 2020, does you current penny investment company have that?
Hit $.27 in 2018 with just 20 million net revenues.
Comparison list of 2021 vs 2018:
1. $40 million NET revenues instead of $20 million
2. SEC Registration nearing completion (filed November 9, 2020)
3. Potential Merger to make us a $100 million NET revenue company.
4. Uplist to higher exchange soon after.
5. New telehealth partnership.
6. New huge square footage facilities in both Miami (11,000 sq ft) and Orlando (3,700 sq ft).
7. Covid Revenue streams, testing and vaccinations.
8. 300% Exponential Growth in 340B Dispensing and Fees.
It is due to ClearMetrX going nationwide in 1st quarter.
Outlook
Looking forward to 2021 and beyond, we look to continue progress on expansion of our ClearMetrX 340B TPA services, as well as our other data analytics platforms. At the end of the first quarter of 2021, we expect the ClearMetrX digital platform will be fully operational, which will allow us to expand our third-party administration services to 340B covered entities nationwide. The Company expects that growth in this revenue component will continue at a level at or above the record growth experienced in fiscal year 2020.
I see the next MM on ask sitting at $.18 behind that $.156. Seems good to me, even though that premarket stuff means nothing really. Have fun! I'll sweep up any intentional bid dumps again today. Growing my shares for the longterm. Heck yah.
And they expect 340 growth increase to surpass the record growth they achieved in 2020. That means they expect it to grow another 323% in 2021. That would be amazing.
Outlook
Looking forward to 2021 and beyond, we look to continue progress on expansion of our ClearMetrX 340B TPA services, as well as our other data analytics platforms. At the end of the first quarter of 2021, we expect the ClearMetrX digital platform will be fully operational, which will allow us to expand our third-party administration services to 340B covered entities nationwide. The Company expects that growth in this revenue component will continue at a level at or above the record growth experienced in fiscal year 2020.
340B revenue for December 31, 2020 was $2.8 million, representing year-over-year growth of 323% compared to the year ended December 31, 2019.
Just one of them
Your statement makes no sense. 4 million shares, it's alive and well.
They can't due to their rules.
They are restricted from doing so. Plain and simple.
Management has the following 2021 Strategic Goals:
• Strive to achieve over $50 million in sales.
• Expansion of COVID-19 testing and vaccination programs.
• Completion of telehealth integration with the roll out of the Eagle Force Digital Passport program.
• Nationwide launch of ClearMetrX 340B TPA services.
• Secure additional not-for-profit healthcare contracts and long-term care facility relationships.
• Achieve full enterprise profitability and earnings growth.
• Become SEC-registered and fully reporting.
• Complete an uplist to a national exchange.
Closing Remarks
2020 was a tough year for many companies including Progressive Care. Despite the tremendous adversity posed by the COVID-19 Pandemic, we believe this was a defining year for our Company, as it points to our resilience as a market leader in healthcare services and shows us that we are on the right track in terms of both our short-term and long-term business plans.
We are grateful for the continued support of our valued shareholders, who have recognized that there is significant value in our approach to healthcare, and that value is not always reflected in just our stock market price. We are also thankful to our employees, who carried us through a very difficult start to 2020. We are very appreciative of their talents, sacrifice and hard work.
Our management team’s vision for Progressive Care is that the healthier we make our patients, the more successful our business will be, and we have not wavered from that vision despite the adversity of the past year. This faith in our vision, along with the hard work of our employees, has produced record-breaking results. We are looking forward to 2021 and beyond to continue to carry out that vision.
Respectfully submitted,
Alan Jay Weisberg
Chief Executive Officer
Once the S1 is completed, yes we will see them and they will clean some clocks.
Bunch of buying today here as well. Good day! The shares just kept dropping to my hands. All those intentional dumps into the bid. Yummy. Great prices too.
Yep, haven't needed to spend a dollar yet today and definitely not selling any shares.
RECENT NEWS Progressive Care Transitions to New Software Platform, Allowing Integration of Data Analytics Business
MIAMI, FL – February 23, 2021 – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce its transition its software platform to Newleaf, a best-in-class pharmacy software solution produced by leading pharmacy software and technology provider, Keycentrix (Keycentrix.com).
Newleaf is highly adaptable and will provide a viable foundation for the Company’s technology development and deployment objectives, including an expansion in its ClearMetRx business, Progressive Care’s wholly owned data analytics company, which features services designed to support health care organizations across the country.
“We believe the transition to Newleaf will accelerate our health-tech evolution,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “The platform is expected to improve our workflows and provide for significant advances in our ability to quickly and effectively share customizable data with healthcare providers and should substantially improve our market positioning in our most scalable and fastest growing segment, which is our reporting capabilities, data management, and data analytics.”
The transition to Newleaf has already taken place at the Company’s primary location and is expected to be completed at all other locations during the next two months.
“We are thrilled to partner with PharmCoRx as they create a pharmacy model that responds to patient and market needs,” said Luis Rodrigues, president of Keycentrix. “At same time, we’re excited to help amplify their data capabilities in meaningful ways.”
RECENT NEWS Progressive Care Transitions to New Software Platform, Allowing Integration of Data Analytics Business
MIAMI, FL – February 23, 2021 – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce its transition its software platform to Newleaf, a best-in-class pharmacy software solution produced by leading pharmacy software and technology provider, Keycentrix (Keycentrix.com).
Newleaf is highly adaptable and will provide a viable foundation for the Company’s technology development and deployment objectives, including an expansion in its ClearMetRx business, Progressive Care’s wholly owned data analytics company, which features services designed to support health care organizations across the country.
“We believe the transition to Newleaf will accelerate our health-tech evolution,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “The platform is expected to improve our workflows and provide for significant advances in our ability to quickly and effectively share customizable data with healthcare providers and should substantially improve our market positioning in our most scalable and fastest growing segment, which is our reporting capabilities, data management, and data analytics.”
The transition to Newleaf has already taken place at the Company’s primary location and is expected to be completed at all other locations during the next two months.
“We are thrilled to partner with PharmCoRx as they create a pharmacy model that responds to patient and market needs,” said Luis Rodrigues, president of Keycentrix. “At same time, we’re excited to help amplify their data capabilities in meaningful ways.”
RECENT NEWS Progressive Care Announces Record December and Full Year 2020 Performance Data
MIAMI, FL – February 8, 2021 – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to report performance data for the month of December and the full year of 2020, which featured robust growth in sales and prescriptions, as well as breakout growth in emerging income streams, including 340B administration fees and COVID-19 Rapid Testing services.
Full Year 2020 Performance Highlights
• Consolidated gross sales across all locations for the twelve months ended December 31, 2020 totaled a Company record $40.6 million, representing year-over-year growth of 23% compared to the twelve months ended December 31, 2019.
• Total prescriptions for the twelve months ended December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months ended December 31, 2019.
• 340B revenue was $2.8 million, representing year-over-year growth of 300% compared to the twelve months ended December 31, 2019.
• Revenues from COVID-19 Rapid Testing totaled approximately $600,000 during 2020 with over 5000 tested.
December 2020 Performance Highlights
• Consolidated gross sales for the month of December 2020 totaled $3.5 million, representing 9% year-over-year growth (compared to December 2019), and 3% sequential monthly growth (compared to November 2020).
• Total prescriptions for the month of December 2020 totaled 46,200, representing 3% year-over-year growth (compared to December 2019), and 8.5% sequential monthly growth (compared to November 2020).
• 340B revenue was approximately $230,000 for the month of December 2020, representing 109% year-over-year growth (compared to December 2019).
• Revenues from COVID-19 Rapid Testing totaled a record $345,000 for the month of December 2020, representing 115% sequential monthly growth (compared to November 2020).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready
operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
Progressive Care stands ready to deliver the same strong service to its clients, patients, and providers in 2021 as the pandemic recedes and a more normalized operating environment reasserts itself, providing a further opportunity for the Company to serve its community as a continued strong force on the virus testing front as well as a key player in the effort to efficiently distribute critical vaccine resources.
Alan Jay Weisberg, CEO and Chairman of Progressive Care, commented, “At some point, you’re going to face a test, and 2020 was a litmus test for many companies. We identified it as such at Progressive Care and worked proactively to innovate, and we emerged stronger than ever. It’s hard to find words to express how proud I am of our team, and we all look forward to a gradually normalizing operational environment in 2021.”
For more information about Progressive Care, please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. https://www.facebook.com/ProgressiveCareUS/ https://twitter.com/ProgressCareUS
PharmCoRx https://www.facebook.com/pharmcorx/ https://twitter.com/PharmCoRx
ClearMetrX https://www.clearmetrx.com/ https://www.facebook.com/clearmetrx/
About Progressive Care: Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
RECENT NEWS Progressive Care Announces Telehealth Partnership with EagleForce Health to Drive myVax™ Digital Passport for COVID-19 Testing and Vaccination
MIAMI, FL – February 16, 2021 – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce a new partnership with EagleForce Health, LLC to integrate its proprietary telehealth platform (“myVax™”) and develop a platform for the Company’s Digital Passport for COVID-19 Testing and Vaccination results.
“The need for a digital passport to help manage our coming post-pandemic environment is paramount, and we believe myVax™ can develop into a market-leading solution to meet that need,” remarked Alan Jay Weisberg, CEO and Chairman of Progressive Care. “This partnership will allow Progressive Care to expand our telehealth presence and scale more of our operations in a geographically agnostic manner through significant exposure to one of the most important opportunities defining the intermediate-term future in the business economy: digital proof of vaccination.”
The myVax™ platform is expected to launch over the coming weeks and to include complete patient scheduling, telehealth, and tele-pharmacy platform services. “Our partnership with Progressive Care is designed to focus on the COVID-19 digital passport roll-out to support the Company’s first line health service providers who see, touch and bring solutions directly to the patient. Phase 1 of the myVax™ platform launch will be made available to patient population well beyond the COVID 19 pandemic. The full scope of our commitment to this partnership will bring transformational outcomes to patient adherence and self-management of disease to the rapidly growing Telehealth marketplace. We are so proud to have Progressive Care as a partner.” said Stanley Campbell, CEO and Chairman of EagleForce Health, LLC.
The platform will manage an individual’s COVID-19 Vaccine and Test Journey documenting all transitions, including healthcare appointments, billing, and telehealth services. This will also include a Digital Passport or Digital Wallet that is QR-coded for registration, verification, and documentation of COVID-19 vaccination and/or test results.
This is expected to provide a powerful tool for various processes that the Company believes will come to depend upon accurate real-time virus spread risk abatement, including merchants such as cruise lines, airlines, sports venues, high-population-density, manufacturing, packing, or shipping facilities, and institutions such as school districts, universities, court proceedings, public transportation systems, and other service providers.
Mr. Weisberg added, “The COVID-19 digital passport roll-out will be our Phase 1 service launch for the myVax™ platform; however, the full scope of this partnership expands well beyond COVID-19 and is expected to powerfully augment our overall positioning in the rapidly growing
Telehealth marketplace. We look forward to providing further updates and additional detail in subsequent communications.”
RECENT NEWS Progressive Care Announces Confidential Submission of Draft Registration Statement
MIAMI, FL – December 2nd, 2020 – Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”) is pleased to announce that on November 9th it confidentially submitted a draft Registration Statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.
This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.
RECENT NEWS Progressive Care Completes Expansion, Launches COVID-19 Rapid Testing at New Orlando Location
MIAMI, FL – February 1, 2021 – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce that its new 3,700 square foot Orlando pharmacy has now officially opened for business as a potent full-service location that is also expected to act as a growth hub for rapid results viral testing services, Covid-19 vaccinations, and 340B third-party administration contracting.
The move will allow for a dramatic expansion in services of PharmCoRx pharmacy medication therapy and medication adherence management, and Covid-19 rapid testing solution.
The new location sits just minutes from Orlando International Airport, which will facilitate ease of access for international and out-of-state travelers in need of rapid results Covid-19 testing services required prior to departure as well as the administration of Covid-19 vaccinations (when available).
“This is a jump from a small, bare-bones, fringe outpost store to a state-of-the-art, full-sized, robotics-equipped hub in one of our largest markets,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “The addition to our end-market footprint here promises to have a strong impact on the performance of our core pharmacy services business, as well as our testing and 340B operations with new 340B covered entities under contract. We anticipate substantial growth as we continue to ramp up our Orlando operations.”
Good morning ProgressiveCare $RXMD
How we work together is by not bid dumping and not letting them refill on bid, IF they want to continue their game. And everyone needs to recognize that when a big ask wall goes up, it is a simplest scare tactic in the book. Then they dump some shares into the bid to enhance the scare tactic hoping to get others to follow suit. The key is to put your own bid orders in and gradually remove the wall.
That falls into a category of it doesn't matter.
Like stockforce has stated below, do you want to chase to $.50 or even better $1
Well let's see, we haven't hit .12 in nearly 5 days and been over .16 every day so that makes it tough to acquire shares at .12, especially when we moving higher and higher.
It's not that you flip, it's that you manipulate it in the process. That's what has ticked people off here.
Exactly, then he is chasing and his 3 million or so that he keeps in reserves won't stop anything at all.
Yah the only company that I have invested in the OTC that is still around and stronger than ever after 6 years. SEC REGISTRATION and uplist here we come.
Isn't that the truth. We need to put a stop to it. He and a few others are manipulating the stock. I have a significant amount of funds and am looking to put an end to their fun. I have got many others on board. Let's do it.
Oh Dubster, well you can continue to make a living on stocks like these, just not this one.
You can't even hold past $.20. I can though, and I have free money to spend to block your future pickups on the bid.
That's not all your doing. Don't worry stockforce and others are ready this time.
Good I'll put my big buys right in front of yours.
Thanks stockforce for sharing the conversation.
UPLIST TO NASDAQ! Is that what you are referring to?
Because when anyone does their Due Diligence and get into the details of any potential reverse split for this company, we actually find that it will make investors buy this stock. Why and for what reason has this company only mentioned a potential reverse split?
I'll answer that: They have only mentioned performing a reverse split if it is needed to get the proper valuation for uplisting to NASDAQ when that time comes. That is different than the version of a reverse split that you are insuating.
The long-term shareholders and newer investors here actual already completed a shareholder vote approving a reverse split if it is needed to get us to $4-$5 per share when the time comes to uplist to NASDAQ and moving off of the OTC which is not institutional investor friendly and doesn't base company value off of fundamentals. For all we know, there may not be one needed or it may be an easy 10 for 1
What's wrong with share price? I am pleased with share price. Good chance we hit $.25 today.
$.2657 in March 2018
Company is a lot different now.
Comparison list of 2021 vs 2018:
1. $40 million NET revenues instead of $20 million
2. SEC Registration nearing completion (filed November 9, 2020)
3. Potential Merger to make us a $100 million NET revenue company.
4. Uplist to higher exchange soon after.
5. New telehealth partnership.
6. New huge square footage facilities in both Miami (11,000 sq ft) and Orlando (3,700 sq ft).
7. Covid Revenue streams, testing and vaccinations.
8. 300% Exponential Growth in 340B Dispensing and Fees.